Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 52Ovarian Neoplasms 40Multiple Myeloma 20Fallopian Tube Neoplasms 13Lymphoma 12Sarcoma 11Carcinoma, Ovarian Epithelial 11Triple Negative Breast Neoplasms 8Recurrence 8Lymphoma, Large B-Cell, Diffuse 8Neoplasms 7Lymphoma, Non-Hodgkin 7Hodgkin Disease 6Neoplasms, Plasma Cell 5Sarcoma, Ewing 4Prostatic Neoplasms 4Neoplasm Metastasis 4Lymphoma, Mantle-Cell 4Burkitt Lymphoma 4Rhabdomyosarcoma 3Osteosarcoma 3Lymphoma, T-Cell, Peripheral 3Leiomyosarcoma 3Breast Neoplasms, Male 3Uterine Cervical Neoplasms 2Solid Tumors 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2

Interventions

Oxaliplatin 200Capecitabine 116S 1 (combination) 106Fluorouracil 105Docetaxel 100Cisplatin 88Leucovorin 75Paclitaxel 71Irinotecan 68apatinib 43sintilimab 42Drug Therapy 42Surgical Procedures, Operative 37Hyperthermic Intraperitoneal Chemotherapy 34pembrolizumab 32Radiotherapy 31Trastuzumab 30Gastrectomy 23Nivolumab 22Epirubicin 22Tegafur 21Bevacizumab 21XELOX 20titanium silicide 19camrelizumab 19tislelizumab 17Ramucirumab 17Carboplatin 16Neoadjuvant Therapy 15Endoscopic Mucosal Resection 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Stomach Neoplasms × liposomal doxorubicin × Clear all
NCT05536102 2023-03-09

The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡